



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Application Number	10/810,260		
					Filing Date	March 26, 2004		
					First Named Inventor	Jiang		
					Group Art Unit	1626		
					Examiner Name	Joseph R. Kosack		
					Attorney Docket Number	22596-537 CON		
U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
U.S. PUBLISHED APPLICATION DOCUMENTS								
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS								
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B3	WO	2004/007531 A2	CYCLIS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE, INC.; BETH ISRAEL DEACONESS MEDICAL CENTER	01/22/04			
	B4	GB	2 011 455 A	IMPERIAL CHEMICAL INDUSTRIES LIMITED	07/11/79			
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
	C14	Petersen et al., "Anlagerung von organischen Schwefelverbindungen an Naphthochinonaldehyde", <i>Liebigs Ann. Chem.</i> , English Abstract only, 764:28-35 (1972)						
	C15	Sugiyama et al., "Aldose reductase catalyzes the oxidation of naphthalene-1,2-dihydrodiol for the formation of <i>ortho</i> -naphthoquinone", <i>Drug Metabolism and Disposition</i> , 27(1):60-67 (1999)						

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail Label: EV 869897598 US
Date of Deposit: May 20, 2008

Page 1 of 1
Attorney Docket No.: 22596-537 CON

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Application Number	10/810,260		
					Filing Date	March 26, 2004		
					First Named Inventor	Jiang		
					Group Art Unit	1626		
					Examiner Name	Joseph R. Kosack		
					Attorney Docket Number	22596-537 CON		
U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
U.S. PUBLISHED APPLICATION DOCUMENTS								
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS								
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication		Translation Yes No	
	B3	WO	2004/007531 A2	CYCLIS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE, INC.; BETH ISRAEL DEACONESS MEDICAL CENTER	01/22/04			
	B4	GB	2 011 455 A	IMPERIAL CHEMICAL INDUSTRIES LIMITED	07/11/79			
OTHER/PRIOR ART/ NON/PATENT LITERATURE DOCUMENTS								
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
	C14	Petersen et al., "Anlagerung von organischen Schwefelverbindungen an Naphthochinonaldehyde", <i>Liebigs Ann. Chem.</i> , English Abstract only, 764:28-35 (1972)						
	C15	Sugiyama et al., "Aldose reductase catalyzes the oxidation of naphthalene-1,2-dihydrodiol for the formation of <i>ortho</i> -naphthoquinone", <i>Drug Metabolism and Disposition</i> , 27(1):60-67 (1999)						

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.